MAHKOTA MEDICAL CENTRE BRINGS HIFU TECHNOLOGY LEARNING TO AN INTERNATIONAL COMMUNITYNOVEMBER 30, 2022 @ 9.23AM
Mahkota Medical Centre (MMC), the first medical facility in Malaysia to introduce the ultrasound-based high-intensity focused ultrasound (USgHIFU) technology, collaborated with Chongqing Medical University to train 25 international clinicians. These clinicians from 11 countries were exposed to the new HIFU technology, providing them with hands-on experience using non-invasive equipment.
“The Third International Training Workshop on Focused Ultrasound Therapy for Tumours” trained these specialists on this revolutionary treatment option for uterine fibroids and adenomyosis. The HIFU technology’s non-invasive feature preserves a woman’s fertility with no blood loss and transfusion, leaves no scars and has been proven to have a shorter recovery time. This training workshop spanning two weeks, was led by Dr Selva, Obstetrician & Gynaecologist, and Reproductive Medicine Specialist of MMC. Participants from Malaysia, Indonesia, Philippines, Egypt, Ethiopia, Mexico, Germany, Singapore, Thailand, Nepal, and Tanzania were exposed to lectures and practical training on the HIFU system and software. Participants were then granted course-completion certificates issued by the Ministry of Science and Technology of the People’s Republic of China – the workshop sponsor. This training session possibly bridges the treatment gap, as women from these 11 countries stand a chance to benefit from this treatment. Dr Selva shared, “As the first hospital to introduce ultrasound-based HIFU technology in the country, we are happy to be able to provide this option to women in Malaysia and globally. Since its availability in July 2021, we have treated over 300 women not only from Malaysia but international patients from Indonesia, the Philippines and Pakistan. I hope this technology and this workshop will propagate this technology globally, enabling more women to preserve their fertility and achieve their dreams of becoming mothers. Liu Hua, L1 Investigator, Division of Integration and Planning, International Cooperation Department of China Ministry of Science and Technology, said, “This innovative medical device and advanced treatment technology will enable people all over the world to enjoy the non-invasive results. While the device is cutting-edge, it is equally important to have the right skill set and knowledge transfer. With this international training course, the specialists can upskill themselves on medical innovations that will improve outcomes for women suffering from adenomyosis and uterine fibroids.”
|
Roche launch Perjeta - Herceptin combination, a post surgery treatment for early breast cancer (eBC)
Keytruda with chemotherapy to be the first line of treatment for patients with advanced lung cancer
|





















































































